Skip to content

Endocrine · Reference monograph

Intranasal GnRH agonist for HPG-axis suppression

Reference compound — not available from Purity Peptides. Shown for research context.

Overview

Nafarelin is a synthetic decapeptide analogue of gonadotropin-releasing hormone developed by Syntex in the late 1970s and early 1980s. Its defining feature is a bulky 3-(2-naphthyl)-D-alanine residue at position 6, which increases hydrophobicity, enhances receptor binding and protects the molecule from enzymatic degradation. Nafarelin was approved by the FDA around 1990 and is marketed as Synarel, with availability varying by country.

Nafarelin has been studied for endometriosis, central precocious puberty and pituitary suppression during assisted reproduction. Because its formulation does not depend on a sustained-release polymer, it has been of interest in pharmaceutical science as an example of non-parenteral peptide delivery, an area where poor bioavailability usually limits peptide drugs. In research settings nafarelin serves as a short-acting GnRH agonist that allows investigators to study the onset and offset of pituitary desensitisation, the relationship between oestrogen suppression and endometrial lesions, and the neuroendocrine control of puberty in experimental models.

Mechanism studied

  1. Nafarelin
  2. GnRH receptor
  3. Pituitary desensitisation
  4. Sex steroids ↓

Nafarelin is a high-affinity agonist at the GnRH receptor on pituitary gonadotrophs. Its initial effect is stimulation of luteinising hormone and follicle-stimulating hormone release, with a short-lived increase in gonadal steroid production. With continued exposure, the receptor desensitises: signalling uncouples, receptor numbers fall and gonadotropin gene expression declines. Ovarian oestradiol and testicular testosterone are subsequently suppressed in published studies. Because oestrogen supports the growth of endometriotic tissue, this hypo-oestrogenic state is the basis of research into endometriosis. Suppression reverses once exposure ends, making nafarelin useful for studying recovery of the reproductive axis.

Research highlights

  • 01Developed by Syntex as one of several potent GnRH agonists designed through position-6 substitution.
  • 02The naphthylalanine residue is a classic example of hydrophobic modification improving peptide potency.
  • 03Comparative studies examined its effects on endometriosis lesions relative to danazol and other agonists.
  • 04Investigated in central precocious puberty research and in pituitary suppression for assisted reproduction.
  • 05Open questions concern the bone-density consequences of hypo-oestrogenism and strategies to offset them in research models.

Latest published research

274 papers on PubMed →

  1. Is there a difference in ovarian hyperstimulation syndrome rates in freeze-all treatment cycles in high-risk patients treated with different GnRH agonist triggers?

    Shah R et al. · Human fertility (Cambridge, England) · 2026 Dec · PMID 42831293

  2. Trends in endometriosis interventions: an interrupted time series analysis following the Australian National Action Plan for Endometriosis (NAPE) 2018

    Chinaka CC et al. · Australian health review : a publication of the Australian Hospital Association · 2025 Aug 7 · PMID 40623680

  3. A study on the efficacy and safety of long-term adjusted low-dose gonadotropin-releasing hormone agonist therapy for uterine fibroids and adenomyosis

    Kashiwabara S et al. · The journal of obstetrics and gynaecology research · 2024 Dec · PMID 39462178

  4. Mechanistic Model for Drug Release from PLGA-Based Biodegradable Implants for In Vitro Release Testing: Development and Validation

    Mittapelly N et al. · ACS applied bio materials · 2024 Nov 18 · PMID 39424342

  5. Anti-Dengue: A Machine Learning-Assisted Prediction of Small Molecule Antivirals against Dengue Virus and Implications in Drug Repurposing

    Gautam S et al. · Viruses · 2023 Dec 27 · PMID 38257744

  6. Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors

    Broni E et al. · International journal of molecular sciences · 2023 Mar 27 · PMID 37047270

  7. Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not?

    Vercellini P et al. · Human reproduction open · 2023 · PMID 37016694

  8. Hereditary Coproporphyria

    Adam MP et al. · · 1993 · PMID 23236641

Live feed from PubMed (NCBI) for “Nafarelin”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.

Registered studies

12 on ClinicalTrials.gov →

From the public ClinicalTrials.gov registry for “Nafarelin”, updated 2026-10-30. Shown for research context only; Purity Peptides products are not for human use.

Key references

  1. [1]Manufacturer's prescribing information — FDA / EMA / ANVISA
  2. [2]PubMed — reviews on nafarelin and endometriosis
  3. [3]WADA — Prohibited List of Substances and Methods

FAQ

  • Nafarelin contains 3-(2-naphthyl)-D-alanine at position 6. This large hydrophobic residue stabilises the peptide's active conformation and resists enzymatic cleavage, making it far more potent than native GnRH at the pituitary receptor.

  • Endometriotic tissue depends on oestrogen. By desensitising the pituitary and lowering ovarian oestradiol output, nafarelin creates a hypo-oestrogenic state that researchers use to examine lesion biology and compare suppression strategies.

  • Nafarelin was approved by the FDA and through national authorisations in Europe, but commercial availability varies by country and has declined over time. Research-grade material is supplied only for laboratory investigation.

FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.

Related compounds

WhatsApp